Eli Lilly and Co (LLY) Shares Bought by Candriam Luxembourg S.C.A.

Candriam Luxembourg S.C.A. boosted its stake in Eli Lilly and Co (NYSE:LLY) by 80.4% during the first quarter, according to its most recent filing with the SEC. The firm owned 156,664 shares of the company’s stock after buying an additional 69,809 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Eli Lilly and were worth $13,178,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. First Command Financial Services Inc. boosted its stake in shares of Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after buying an additional 84 shares during the last quarter. Financial Architects Inc boosted its stake in shares of Eli Lilly and by 4.5% in the third quarter. Financial Architects Inc now owns 1,423 shares of the company’s stock valued at $114,000 after buying an additional 61 shares during the last quarter. Tarbox Group Inc. boosted its stake in shares of Eli Lilly and by 0.7% in the third quarter. Tarbox Group Inc. now owns 1,539 shares of the company’s stock valued at $124,000 after buying an additional 11 shares during the last quarter. LeJeune Puetz Investment Counsel LLC purchased a new stake in shares of Eli Lilly and during the fourth quarter valued at approximately $136,000. Finally, Physicians Financial Services Inc. boosted its stake in shares of Eli Lilly and by 6.1% in the third quarter. Physicians Financial Services Inc. now owns 1,738 shares of the company’s stock valued at $139,000 after buying an additional 100 shares during the last quarter. 75.15% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, April 25th. The company reported $0.98 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.96 by $0.02. The company had revenue of $5.23 billion for the quarter, compared to analyst estimates of $5.22 billion. Eli Lilly and had a net margin of 12.90% and a return on equity of 24.74%. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period last year, the business posted $0.83 earnings per share.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 9th. Investors of record on Monday, May 15th will be issued a dividend of $0.52 per share. The ex-dividend date is Thursday, May 11th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.66%. Eli Lilly and’s payout ratio is 80.62%.

WARNING: “Eli Lilly and Co (LLY) Shares Bought by Candriam Luxembourg S.C.A.” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2017/05/20/candriam-luxembourg-s-c-a-acquires-69809-shares-of-eli-lilly-and-co-lly-updated.html.

Several equities research analysts recently commented on the company. Jefferies Group LLC reissued a “buy” rating and set a $97.00 target price (up previously from $95.00) on shares of Eli Lilly and in a report on Saturday, March 11th. Citigroup Inc boosted their target price on Eli Lilly and from $92.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, April 19th. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $87.00 target price on the stock in a report on Friday, February 3rd. Morgan Stanley cut Eli Lilly and from an “overweight” rating to an “equal weight” rating and set a $82.00 target price on the stock. in a report on Monday, April 17th. Finally, Vetr cut Eli Lilly and from a “hold” rating to a “sell” rating and set a $74.30 price target on the stock. in a report on Tuesday, January 31st. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and thirteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $87.56.

In related news, SVP Enrique A. Conterno sold 25,000 shares of the firm’s stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $82.76, for a total transaction of $2,069,000.00. Following the sale, the senior vice president now directly owns 114,217 shares in the company, valued at $9,452,598.92. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction on Thursday, March 30th. The stock was sold at an average price of $84.67, for a total transaction of $17,780,700.00. Following the sale, the insider now owns 124,690,804 shares in the company, valued at $10,557,570,374.68. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

12 Month Chart for NYSE:LLY

Receive News & Ratings for Eli Lilly and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply